Research programme: gene-silencing oligonucleotides - Idera Pharmaceuticals

Drug Profile

Research programme: gene-silencing oligonucleotides - Idera Pharmaceuticals

Alternative Names: 3GA platform - Idera; Gene-silencing oligonucleotides - Idera; GSO - Idera; Third generation antisense platform - Idera; TLR antagonists for B cell lymphomas - Idera Pharmaceuticals; TLR anti-sense oligonucleotides - Idera

Latest Information Update: 12 Aug 2016

Price : $50

At a glance

  • Originator Idera Pharmaceuticals
  • Developer Idera Pharmaceuticals; Leiden University; National Cancer Institute (USA)
  • Class Antisense oligonucleotides; Oligonucleotides
  • Mechanism of Action Apolipoprotein B inhibitors; Gene silencing; Immunomodulators; MicroRNA inhibitors; PCSK9 protein inhibitors; RNA interference; Toll-like receptor 7 antagonists; Toll-like receptor 8 antagonists; Toll-like receptor 9 antagonists; Toll-like receptor antagonists; Toll-like receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; B cell lymphoma; Facioscapulohumeral muscular dystrophy; Hypercholesterolaemia; Inflammation; Interstitial cystitis; Ischaemia; Psoriasis; Uveitis

Most Recent Events

  • 15 Mar 2017 Idera plans clinical trials for its liver-targeting 3GA therapeutic in 2018
  • 15 Mar 2017 Idera announces intention to submit IND for its liver-targeting 3GA therapeutic in 2018
  • 31 Dec 2015 Preclinical trials in Facioscapulohumeral muscular dystrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top